文献速递鼻科

生物治疗对严重慢性鼻窦炎伴鼻息肉的真实世界有效性

Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps.
PubMed 文献 · Rhinology · 2022-01-01

这项真实世界研究纳入70例长期鼻用激素、全身激素和/或鼻内镜鼻窦手术后仍控制不佳的严重慢性鼻窦炎伴鼻息肉患者,其中49例接受度普利尤单抗、21例接受奥马珠单抗治疗。治疗3个月和6个月后息肉评分显著下降,生活质量参数和嗅觉改善,超过90%患者呈中度至优异应答,两种治疗总体应答无差异。

要点

  • 鼻息肉评分在治疗3个月和6个月后均显著下降。
  • 生活质量参数和嗅觉功能在治疗3个月后即有改善。
  • 超过90%患者对治疗呈中度至优异应答,两种治疗间总体应答无差异。

核心结论

  • 这项真实世界研究显示度普利尤单抗和奥马珠单抗治疗严重慢性鼻窦炎伴鼻息肉有效。

研究设计与样本

  • 按方案分析纳入因控制不佳的慢性鼻窦炎伴鼻息肉而有生物制剂治疗指征的患者,尽管已接受长期鼻用激素治疗、全身激素使用和/或鼻内镜鼻窦手术。
  • 共评估70例连续患者,其中49例接受度普利尤单抗治疗,21例接受奥马珠单抗治疗。
  • 评估基线人口学、病史和合并症、息肉评分、生活质量和嗅觉(使用Sniffin' Sticks),并在3个月和6个月后随访。

主要发现

  • 息肉评分在3个月和6个月后显著下降。
  • 生活质量参数和嗅觉功能改善。
  • 超过90%患者对治疗呈中度至优异应答,两种治疗间总体应答无差异。
  • 嗅觉在三分之二患者中改善,但三分之一患者在治疗6个月后仍为嗅觉丧失。
  • 按指南标准评估,仅5例患者应答不充分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: During the last two years, three different monoclonal antibodies have been approved in many countries for the treatment of patients suffering from severe chronic rhinosinusitis with nasal polyps (CRSwNP). Their efficacy has been demonstrated through large double-blind placebo-controlled clinical studies. Until now, only very limited reports on real-world data regarding this therapy have been published. METHODS: This per protocol analysis included patients with an indication for biological treatment because of uncontrolled CRSwNP, despite long-term nasal steroid treatment, systemic steroid use and/ or endonasal sinus surgery. Baseline data on demographics, medical history and comorbidities, polyp score, quality of life and sense of smell (using Sniffin' Sticks) were assessed and a treatment with either dupilumab or omalizumab was started. The patients were followed up after three and six months. The changes in polyp score, quality-of-life measures and olfaction were noted. RESULTS: 70 consecutive patients were evaluated during the study. Of the patients, 49 were treated with dupilumab and 21 with omalizumab. The polyp score decreased significantly after three and six months, and the quality-of-life parameters and olfaction increased. More than 90% of patients showed a moderate to excellent response to the therapy and there was no difference in the overall response between the two treatments. Olfaction improved in two thirds of the patients, but one third was still anosmic after six months treatment. CONCLUSIONS: This real-world study shows the effectiveness of the monoclonal antibodies dupilumab and omalizumab in the treatment of severe CRSwNP. Nasal polyp scores and quality-of-life parameters as well as measured olfactory function were improved after just three months. The response after guideline-based criteria was insufficient only in 5 patients of this cohort.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Haxel BR, Hummel T, Fruth K, et al. Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps. Rhinology. 2022. PMID: 36150163. doi:10.4193/Rhin22.129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。